Skip to main content
Premium Trial:

Request an Annual Quote

CBLPath, UPMC Team on NGS-based Thyroid Cancer Testing

NEW YORK (GenomeWeb) – CBLPath today said that it has signed a preferred partnership agreement with the University of Pittsburgh Medical Center Division of Molecular and Genomic Pathology covering next-generation sequencing-based thyroid cancer testing.

Under the deal, CBLPath will offer UPMC's NGS-based assay through its cytopathology program, which interprets more than 40,000 thyroid FNAs annually with one of the lowest indeterminate rates in the US, according to the firm. UPMC offers the NGS-based ThyroSeq v.2 assay, an expanded version of the initial ThyroSeq panel that detects more than 400 mutations and chromosomal rearrangements in over 60 key thyroid cancer genes.

Financial and other terms of the agreement were not disclosed.

Rye Brook, NY-based CBLPath is owned by pathology services provider Sonic Healthcare USA.